These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29579316)

  • 1. Obstacles to improving outcomes in the treatment of uveal melanoma.
    Tsai KK; Bollin KB; Patel SP
    Cancer; 2018 Jul; 124(13):2693-2703. PubMed ID: 29579316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Metastatic Uveal Melanoma: Progress and Challenges.
    Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
    BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
    Barker CA; Salama AK
    J Natl Compr Canc Netw; 2018 May; 16(5S):646-650. PubMed ID: 29784747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for uveal melanoma metastasis. Literature review.
    Missotten GS; Keunen JE
    Bull Soc Belge Ophtalmol; 2004; (294):13-22. PubMed ID: 15682915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uveal Melanoma UK National Guidelines.
    Nathan P; Cohen V; Coupland S; Curtis K; Damato B; Evans J; Fenwick S; Kirkpatrick L; Li O; Marshall E; McGuirk K; Ottensmeier C; Pearce N; Salvi S; Stedman B; Szlosarek P; Turnbull N;
    Eur J Cancer; 2015 Nov; 51(16):2404-12. PubMed ID: 26278648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.
    Rao PK; Barker C; Coit DG; Joseph RW; Materin M; Rengan R; Sosman J; Thompson JA; Albertini MR; Boland G; Carson Iii WE; Contreras C; Daniels GA; DiMaio D; Durham A; Fields RC; Fleming MD; Galan A; Gastman B; Grossman K; Guild V; Johnson D; Karakousis G; Lange JR; ; Margolin K; Nath S; Olszanski AJ; Ott PA; Ross MI; Salama AK; Skitzki J; Swetter SM; Wuthrick E; McMillian NR; Engh A
    J Natl Compr Canc Netw; 2020 Feb; 18(2):120-131. PubMed ID: 32023525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma.
    Vasalaki M; Fabian ID; Reddy MA; Cohen VM; Sagoo MS
    Br Med Bull; 2017 Jan; 121(1):107-119. PubMed ID: 28069617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
    Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
    Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality of evidence about effectiveness of treatments for metastatic uveal melanoma.
    Augsburger JJ; Corrêa ZM; Shaikh AH
    Trans Am Ophthalmol Soc; 2008; 106():128-35; discussion 135-7. PubMed ID: 19277228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uveal melanoma.
    Kashyap S; Meel R; Singh L; Singh M
    Semin Diagn Pathol; 2016 May; 33(3):141-7. PubMed ID: 26972224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
    Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
    Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology and management of uveal melanoma.
    Sato T; Han F; Yamamoto A
    Curr Oncol Rep; 2008 Sep; 10(5):431-8. PubMed ID: 18706273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveal melanoma: implications of tumor doubling time.
    Singh AD
    Ophthalmology; 2001 May; 108(5):829-31. PubMed ID: 11319992
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of metastatic malignant uveal melanoma].
    Jäckel A; Bock M; Deichmann M; Waldmann V; Näher H
    Hautarzt; 2001 Feb; 52(2):98-103. PubMed ID: 11244899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.
    Star P; Goodwin A; Kapoor R; Conway RM; Long GV; Scolyer RA; Guitera P
    Eur J Cancer; 2018 Mar; 92():48-53. PubMed ID: 29413689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uveal melanoma: a rare malignancy.
    Gragoudas ES; Egan KM
    Ophthalmology; 2000 Aug; 107(8):1441-2. PubMed ID: 10919884
    [No Abstract]   [Full Text] [Related]  

  • 19. Invited commentary. Uveal melanoma: implications of tumor doubling time.
    O'Brien J
    Ophthalmology; 2001 May; 108(5):831-2. PubMed ID: 11780648
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline.
    Weis E; Surgeoner B; Salopek TG; Cheng T; Hyrcza M; Kostaras X; Larocque M; McKinnon G; McWhae J; Menon G; Monzon J; Murtha AD; Walker J; Temple-Oberle C
    Curr Oncol; 2023 Dec; 31(1):24-41. PubMed ID: 38275828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.